Company intelligence / Profile preview

外贸公司

Beijing, Beijing, Chinadiiamo.cn ↗

Ownership: Private
Development stage: Commercial

Overview

Sinopharm oversees a vast portfolio of pharmaceutical R&D, manufacturing, and distribution companies. Its COVID‑19 vaccine was among the first approved globally. The group’s products include vaccines for COVID‑19, hepatitis A, polio, influenza (including H5N1/H1N1), hand-foot-and-mouth disease (EV71), varicella/chickenpox and more. Subsidiaries also develop small molecules and biologics for various indications.

Modalities: VaccineSmall moleculeBiologic
Industry: Pharma

Partnerships

Pfizer partnership announced April 2023 for drug approvals in China through joint efforts with Sinopharm Group.

Beyond the preview

Go deeper on 外贸公司.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 外贸公司.

Explore the full profile